宜明昂科-B：IMM2510/AXN-2510获美国FDA批准IND申请

Core Viewpoint - The company has received FDA approval for the IND application of IMM2510/AXN-2510, a bispecific antibody developed in collaboration with InstilBio, Inc. [1] Group 1 - The clinical trial for IMM2510/AXN-2510 is planned to start by the end of 2025, focusing on patients with recurrent/refractory solid tumors in a Phase 1b/2 study [1] - The trial aims to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of the drug in solid tumor patients [1] - Concurrently, a Phase 2 study in China is ongoing, assessing IMM2510/AXN-2510 in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC), with data expected to be released in the second half of 2025 [1]